Stefan Barth
Impact in
- Immunology top 1%
- Toxin Mechanisms and Immunotoxins
- Immunotherapy and Immune Responses
- Biotechnology top 0.5%
- Transgenic Plants and Applications
Papers in
- Immunology 101
- Toxin Mechanisms and Immunotoxins 70
- Immunotherapy and Immune Responses 20
-
- RNA Interference and Gene Delivery 19
- Glycosylation and Glycoproteins Research 18
- Co-authors
- Rainer Fischer (55 shared papers)Mehmet Kemal Tur (35 shared papers)Michael Hühn (36 shared papers)Andreas Engert (29 shared papers)Theo Thepen (28 shared papers)Ahmad Fawzi Hussain (14 shared papers)Michael Stöcker (16 shared papers)Volker Diehl (16 shared papers)
- Journals
- International Journal of Cancer (9 papers)Biomedicines (9 papers)Cancer Letters (7 papers)International Journal of Molecular Medicine (7 papers)Current Pharmaceutical Design (6 papers)
- Partner nations
- GermanySouth AfricaUnited States
In The Last Decade
Stefan Barth
240 papers receiving 5.3k citations
Peers
Comparison fields: 5 of 146
- Immunology 1.7k
- Biotechnology 580
- Radiology, Nuclear Medicine and Imaging 1.3k
- Oncology 1.0k
- Molecular Biology 2.2k
Countries citing papers authored by Stefan Barth
This map shows the geographic impact of Stefan Barth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Barth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Barth more than expected).
Fields of papers citing papers by Stefan Barth
This network shows the impact of papers produced by Stefan Barth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Barth. The network helps show where Stefan Barth may publish in the future.
Co-authors
The 25 scholars most cited alongside Stefan Barth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 251 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 281 | |
| 2 | 2000 | 152 | |
| 3 | 2003 | 148 | |
| 4 | 1997 | 120 | |
| 5 | 2008 | 97 | |
| 6 | 2017 | 96 | |
| 7 | 2018 | 88 | |
| 8 | 2018 | 81 | |
| 9 | 2003 | 80 | |
| 10 | 2008 | 79 | |
| 11 | 2011 | 69 | |
| 12 | 2000 | 69 | |
| 13 | 1999 | 66 | |
| 14 | 2011 | 65 | |
| 15 | 2000 | 64 | |
| 16 | 1996 | 64 | |
| 17 | 2013 | 61 | |
| 18 | 2015 | 61 | |
| 19 | Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. | 2001 | 59 |
| 20 | 2003 | 56 |
About Stefan Barth
Stefan Barth is a scholar working on Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Oncology and Biotechnology, having authored 251 papers that have together received 5.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (90 papers), Toxin Mechanisms and Immunotoxins (70 papers), Transgenic Plants and Applications (26 papers), CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (20 papers), RNA Interference and Gene Delivery (19 papers), Glycosylation and Glycoproteins Research (18 papers) and Virus-based gene therapy research (15 papers). The work is most often cited by research in Immunology (1.7k citations), Biotechnology (580 citations), Radiology, Nuclear Medicine and Imaging (1.3k citations), Oncology (1.0k citations) and Molecular Biology (2.2k citations). Stefan Barth has collaborated with scholars based in Germany, South Africa and United States. Frequent co-authors include Rainer Fischer, Mehmet Kemal Tur, Michael Hühn, Andreas Engert, Theo Thepen, Ahmad Fawzi Hussain, Michael Stöcker, Volker Diehl, B. Matthey and Shivan Chetty. Their work appears in journals such as International Journal of Cancer, Biomedicines, Cancer Letters, International Journal of Molecular Medicine and Current Pharmaceutical Design.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.